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Tetrahydrobiopterin Supplementation Improves Endothelial Function
But Does Not Alter Aortic Stiffness in Patients With Rheumatoid
Arthritis
Kaisa M. M€aki-Pet€aj€a, PhD; Lisa Day, BSc;† Joseph Cheriyan, MA, FRCP; Frances C. Hall, FRCP, DPhil; Andrew J. K. €Ost€or, MBBS, FRACP;
Nicholas Shenker, FRCP, PhD; Ian B. Wilkinson, FRCP, DM
Background-—Rheumatoid arthritis is a systemic inﬂammatory condition associated with increased cardiovascular risk that may be
due to underlying endothelial dysfunction and subsequent aortic stiffening. We hypothesized that supplementation with
tetrahydrobiopterin (BH4) would recouple endothelial nitric oxide synthase and thus improve endothelial function and consequently
reduce aortic stiffness.
Methods and Results-—We conducted 2 randomized, double-blinded, placebo-controlled crossover studies examining 2 separate
regimens: an acute regimen, with a single dose of BH4 400 mg versus placebo (n=18), and a short-term regimen, composed of a 1-
week treatment with BH4 400 mg once daily versus placebo (n=15). Flow-mediated dilatation and aortic pulse wave velocity were
studied 4 times, before and after each treatment phase. Acute BH4 supplementation led to an improvement of ﬂow-mediated
dilatation, whereas placebo had no effect (meanSD of effect difference 2.564.79%; P=0.03). Similarly, 1-week treatment with
BH4 improved endothelial function, but there was no change with placebo (meanSD of effect difference 3.505.05%; P=0.02).
There was no change in aortic pulse wave velocity following acute or short-term BH4 supplementation or placebo (meanSD of
effect difference: acute 0.090.67 m/s, P=0.6; short-term 0.031.46 m/s, P=0.9).
Conclusion-—Both acute and short-term supplementation with oral BH4 improved endothelial function but not aortic stiffness. This
result suggests that BH4 supplementation may be beneﬁcial for patients with rheumatoid arthritis by improving endothelial
dysfunction and potentially reducing risk of cardiovascular disease. There appears to be no causal relationship between endothelial
function and aortic stiffness, suggesting that they occur in parallel, although they may share common risk factors such as
inﬂammation. ( J Am Heart Assoc. 2016;5:e002762 doi: 10.1161/JAHA.115.002762)
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R heumatoid arthritis (RA) and other chronic inﬂammatorydiseases are associated with increased premature
mortality, mostly due to an excess of cardiovascular disease
(CVD).1,2 A number of underlying mechanisms have been
proposed, including endothelial dysfunction. Reduced nitric
oxide (NO) bioavailability or endothelial dysfunction is thought
to be a key early step in the initiation of atherosclerosis and
predicts future CVD-related events in a variety of populations,
improving risk classiﬁcation beyond the Framingham Heart
Study scores.3,4 We and others have demonstrated that RA
patients have endothelial dysfunction,5–9 which can be
improved with anti-inﬂammatory therapies.10–12 Aortic stiff-
ening, an independent risk factor for CVD,13 has also been
implicated. Several groups have reported increased aortic
pulse wave velocity (aPWV) in RA and suggested that this
could be a consequence of endothelial dysfunction.10,14–16
Previous studies suggested a link between endothelial
function and stiffness of muscular arteries,17,18 but whether
endothelial function is causally related to aortic stiffness is
unknown.
The mechanism of endothelial dysfunction in RA is
incompletely understood, but reduced tetrahydrobiopterin
(BH4) availability or stability
19 and increased production of
reactive oxygen species have been suggested.20 Under basal
conditions, endothelial nitric oxide synthase (eNOS) is
responsible for NO production, but during inﬂammation,
inducible NOS is also expressed in arterial endothelial cells.
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Inducible NOS activation impairs vasorelaxation in vitro, at
least in part, by limiting availability of BH4 to eNOS,
21 and we
have demonstrated in vivo that inducible NOS activation in RA
is independently related to endothelial function.9 BH4 deﬁ-
ciency is thought to lead to eNOS uncoupling, in which
electrons ﬂowing from the reductase domain to the oxyge-
nase domain are diverted to molecular oxygen rather than
L-arginine, leading to production of superoxide (O2
) rather
than NO.22 Increased release of myeloperoxidase from
activated neutrophils may also play an important role in
endothelial dysfunction in RA. Myeloperoxidase catalytically
consumes NO and increases the production of reactive
oxygen species, subsequently leading to uncoupling of
eNOS20 and oxidation of BH4 to inactive BH2.
19,23,24 We and
others have shown that circulating myeloperoxidase levels are
elevated in patients with RA9,25 and independently predict
endothelial dysfunction in patients with unstable coronary
disease26 and RA.9 Inﬂammation appears to reduce BH4
bioavailability, which may in part mediate the endothelial
dysfunction present in RA; therefore, supplementation with
BH4 may be a reasonable therapeutic option to restore normal
eNOS function and thus endothelial function in RA. Previous
studies have demonstrated that intra-arterial administration of
BH4 improves endothelium-dependent dilation in patients with
hypercholesterolemia,27 coronary artery disease,28 and type II
diabetes.29 Oral BH4 supplementation improves endothelial
function in elderly participants,30 in long-term smokers,31 and
in patients with hypercholesterolemia32 and hypertension.33
No studies to date, however, have investigated the effects of
BH4 in patients with RA. Moreover, it is unclear if improve-
ment of endothelial function would lead to a reduction of
aortic stiffness or if other mechanisms are responsible for
increased aortic stiffness.
Our aim was to test the hypotheses (1) that oral BH4
supplementation would improve endothelial function in
patients with RA and (2) that an improvement of endothe-
lial function would lead to subsequent amelioration of
aortic stiffening, providing evidence about the causal
relationship between endothelial function and aortic stiff-
ness; BH4 is thought to have little direct effect on
inﬂammation per se.
Methods
Study Population
Overall, 33 patients with active RA (disease activity score
[DAS28] >3.5) who met the 1987 American Rheumatism
Association criteria were recruited from the rheumatology
clinics at Addenbrooke’s Hospital, Cambridge, United Kingdom.
Patients with manifest CVD, untreated hypertension (blood
pressure ≥140/90 mm Hg), diabetes, hypercholesterolemia
(total cholesterol ≥6.5 mmol/L), or renal disease and current
smokers were excluded because these conditions are associ-
ated with endothelial dysfunction and arterial stiffening.34 To
determine whether baseline endothelial function and aortic
stiffness were abnormal in RA patients, 33 age- and sex-
matched healthy control participants were randomly selected
fromour database to compare baseline endothelial function and
aortic stiffness. A favorable ethics opinion was obtained from
the National Research Ethics Service, and written informed
consent was obtained from each participant prior any study
procedures.
Pilot Proof-of-Concept Study
We conducted a small pilot study in 5 healthy nonsmoking
control participants (mean age 276 years) to test whether a
single dose of BH4 400 mg would improve endothelial
function. We found that ﬂow-mediated dilatation (FMD)
response increased (from 5.791.77% to 11.374.05%;
P=0.009), and there was a signiﬁcant change in the baseline
diameter (from 3.77.52 to 4.100.62 mm; P=0.008);
however, there was no change in mean arterial pressure
(P=0.1) or aPWV (P=0.2). Data are presented as meanSD,
and signiﬁcance was determined using the paired Student t
test. Based on these pilot data, the 400 mg once-daily dose
was deemed sufﬁcient for the main study in RA patients and
was similar to doses used previously in other conditions.19,33
Experimental Protocol
The present study was conducted in a randomized, double-
blind, crossover manner. To determine whether acute
changes were sustained, patients were allocated to 1 of 2
groups: acute or short-term BH4 supplementation.
In the acute study, participants made two 6-hour visits to
the vascular laboratory (Figure 1A). On day 1, following the
baseline measurement of endothelial function, aortic stiff-
ness, DAS28, and venous blood sampling, participants
received a single oral dose of BH4 400 mg or placebo
(random assignment). At 3 hours after the administration of
BH4 or placebo, the hemodynamic measurements were
repeated. A 3-hour time point was chosen based on published
pharmacokinetic data.35 One week later, the same protocol
was followed, and participants again received either BH4 or
placebo.
In the short-term supplementation study, participants
made 4 visits, each separated by 1 week. Participants
received BH4 400 mg once daily or placebo (random order),
each for 1 week, with 1-week washout between treatments
(Figure 1B). All hemodynamic measurements were assessed
at baseline and at the end of each 7-day treatment period
(treatment 1, washout, and treatment 2). Blood was drawn at
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each time point for the measurement of biochemical markers,
and DAS28 was calculated.
BH4 Tablets
BH4 was given in a form of sapropterin dihydrochloride (6R-
BH4). 6R-BH4 is the synthetic form of naturally occurring BH4
(BioMarin Pharmaceutical Inc) and is approved for treatment
of BH4-responsive phenylketonuria.
Hemodynamic Measurements
All studies were conducted in a quiet, temperature-controlled
room. Blood pressure was recorded in the brachial artery
using a validated oscillometric technique (HEM-705CP; Omron
Corp). Radial artery waveforms were obtained with a high-
ﬁdelity micromanometer (SPC-301; Millar Instruments) from
the wrist, and a corresponding central waveform was
generated using a validated transfer function (Sphygmocor;
AtCor Medical). Augmentation index (AIx), a composite
measure of wave reﬂection, mean arterial pressure and heart
rate were determined using the integrated software. Aortic
and brachial pulse wave velocities were measured, as
previously described.36
Endothelial function was assessed in the brachial artery
using the FMD technique.37 Vessel diameter was measured
using high-resolution vascular ultrasound (Acuson Aspen;
Siemens AG) with a 10.0-MHz linear-array transducer.
Brachial artery diameter was measured continuously for
1 minute at baseline and for a further 5 minutes following
cuff deﬂation. The cuff was placed below (distal to) the
ultrasound transducer and inﬂated to 200 mm Hg for 5 min-
utes. After return to baseline, vessel diameter was again
measured continuously for 5 minutes following administration
of 25 lg of sublingual glyceryl trinitrate. FMD was deﬁned as
the maximum percentage increase in vessel diameter during
reactive hyperemia; glyceryl trinitrate–mediated dilatation was
deﬁned as the maximum percentage increase in vessel
diameter after sublingual glyceryl trinitrate. FMD recordings
were analyzed ofﬂine by a blinded operator using Cardiovas-
cular Suite Software (Quipu).
Laboratory Measurements and DAS28
Fasting lipid proﬁle, high-sensitivity C-reactive protein (CRP),
and erythrocyte sedimentation rate (ESR) were determined
using standard methodology at the Biochemistry Laboratory
at Addenbrooke’s Hospital.
DAS28 is a validated composite disease activity score. The
components of DAS28 include the number of swollen and
tender joints from 28 assessed joints, ESR, and patient-
assessed visual analog score of overall well-being (scale 0–
100). DAS28 was calculated as described previously.38
Data Analysis
The primary outcome of the study was the difference in FMD
response between BH4 and placebo treatments. Secondary
outcomes were differences in aPWV between treatments, the
relationship between changes in aPWV and FMD, and the
relationship between CRP and disease activity and change in
FMD and aPWV.
Based on our pilot data and published data on BH4
supplementation, we calculated that a total of 15 patients (per
Visit 1
Baseline 1
BH4
or
Placebo
After 
Treatment 1 7 days3 hours
Visit 2
Baseline 2
BH4
or
Placebo
After 
Treatment 23 hours
Visit 3 Visit 4Visit 1 Visit 2
Baseline 1
BH4
or
Placebo After 
Treatment 1
7 days
Baseline 2
BH4
or
Placebo
Washout
After 
Treatment 2
7 days7 days
A
B
Figure 1. Schema of the study design. A, All participants made 2 visits, separated by 1 week. At each
time point, blood pressure, arterial stiffness, and endothelial function were assessed, and a blood sample
was taken. B, All participants made 4 visits to the unit on days 0, 7, 14, and 21. At each visit, blood
pressure, arterial stiffness, endothelial function, and disease activity were assessed, and a blood sample
was taken. BH4 indicates tetrahydrobiopterin.
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study) were needed to enter the 2-treatment crossover study
to provide >80% power at P<0.05 to detect a 4.0-U difference
in FMD response between treatments with an SD of 5.0. Data
were analyzed using SPSS software (version 21.0; IBM Corp).
Two-way repeated-measures ANOVA was used to investigate
the effect of the treatment. Custom hypothesis testing
(simple) of within-participant contrasts was performed for
comparison of BH4 versus placebo, in which treatment order
was entered as a between-participant factor to investigate
whether the order in which BH4 and placebo were received
inﬂuenced the outcome. In post hoc tests, the effect of
individual treatments was determined using paired Student t
tests with Bonferroni adjustment for 2 comparisons. In
addition, in post hoc tests, the use of methotrexate (MTX)
was entered as a between-participant factor to establish
whether dyhydrofolate reductase inhibitor use inﬂuenced the
BH4 response. For the skewed variables (CRP and ESR), log-
transformed values were used for the analyses. Differences
between the RA and control groups were determined using
the unpaired Student t test. A probability of <0.05 was
considered signiﬁcant. Data are given as meanSD.
The authors had full access to the data and take full
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
Results
Thirty-three patients with active RA (mean DAS28 4.211.06)
were studied before and after oral BH4 and placebo. The mean
age of the participants was 5712 years, and 27 were
female. Overall, 18 and 15 participants concluded the acute
and short-term supplementation studies, respectively. There
were no differences in age, BMI, DAS28, CRP, ESR, or blood
pressure between groups; however, total cholesterol was
slightly higher in the participants allocated to the short-term
treatment group (4.40.9 versus 5.41.1 mmol/L; P=0.01).
Baseline characteristics are detailed by group in Table 1.
Acute BH4 Supplementation
The effect of BH4 supplementation on hemodynamics and
vascular function are detailed in Table 2. Following a single dose
of BH4, there was a signiﬁcant increase in the FMD response,
whereas placebo had no effect (+3.574.14% versus
+1.013.12%, between treatments; P=0.03) (Figure 2A). The
order in which the treatments were given did not affect the
outcome (P=0.8). Baseline diameter of brachial artery or
response to sublingual glyceryl trinitrate did not change following
the treatment. There were no signiﬁcant differences between the
changes in blood pressure, heart rate, AIx, brachial pulse wave
velocity, or aPWV (Figure 2B) following BH4 or placebo.
Short-Term BH4 Supplementation
The 1-week treatment with BH4 led to a signiﬁcant increase in
FMD compared with placebo (+3.694.90% versus
+0.192.51%, between treatments; P=0.02) (Figure 2C).
The order in which the treatments were given did not affect
the outcome (P=0.7). Again, there was no change in blood
pressure or aPWV (Figure 2D).
Seventeen of the 33 RA patients were receiving MTX, a
dyhydrofolate reductase inhibitor, at the time of the study.
Post hoc testing demonstrated that MTX had no impact on the
effect of BH4 on endothelial function (P=0.34) for the
drug9visit9MTX interaction. If anything, there was a non-
signiﬁcant trend demonstrating that those on MTX had
greater improvement of FMD following BH4 in comparison
to those not on MTX (+4.65.0% versus +2.493.40%;
P=0.18,). This was despite no difference in baseline FMD
(P=0.9) or brachial artery diameter (P=0.98).
The Effect of BH4 on Inﬂammatory Markers and
Disease Activity
Following short-term supplementation with BH4 and placebo,
there were no changes in CRP (0.792.6 versus
0.933.17 mg/L; P=0.9), ESR (07 versus 15 mm/h;
P=0.6), or DAS28 (0.020.46 versus 0.090.43; P=0.4)
(Table 2).
There was no correlation between the change in FMD and
change in aPWV following BH4 (R=0.27; P=0.20); however, the
change in FMD after BH4 correlated negatively with age
(R=0.44; P=0.01). Baseline aPWV was signiﬁcantly (P<0.05)
correlated with mean arterial pressure (R=0.52), age (R=0.52),
CRP (R=0.39), and ESR (R=0.66).
Baseline Comparison With Healthy Controls
The mean age of the healthy control group was 5611 years.
At baseline, RA patients had reduced endothelial function in
comparison to control participants (FMD 3.392.36% versus
6.163.63%; P=0.001). After treatment with BH4, the FMD
response was no longer different between RA patients and
controls (6.824.83% versus 6.163.63%; P=0.5). Baseline
aPWV was higher in the RA group compared with controls
(7.831.80 versus 6.81.03 m/s; P=0.006), whereas blood
pressure did not differ between the groups (Table 1).
Discussion
The main ﬁndings of the present study are that both acute and
short-term therapy with BH4 signiﬁcantly improves endothelial
function, as assessed by vasodilatory response to reactive
DOI: 10.1161/JAHA.115.002762 Journal of the American Heart Association 4
BH4 Improves Endothelial Function in RA M€aki-Pet€aj€a et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 29, 2016http://jaha.ahajournals.org/Downloaded from 
hyperemia in patients with active RA, but does not affect
blood pressure, AIx, aPWV, or brachial pulse wave velocity.
These ﬁndings suggest that modulation of endothelial function
does not ameliorate arterial stiffness in RA.
The current study demonstrates, for the ﬁrst time, that oral
BH4 supplementation improves endothelial function in
patients with RA by 3.5%, restoring it to levels comparable
to those of healthy controls. The improvement of FMD was
inversely associated with age, suggesting that endothelial
dysfunction in younger RA patients may be more reversible
than in older patients. FMD has been validated recently as a
surrogate marker of future cardiovascular risk. Yeboah et al
demonstrated that FMD is a predictor of incident cardiovas-
cular events and that it improves the classiﬁcation of
participants as low, intermediate, and high CVD risk com-
pared with the Framingham risk score in a large population-
based cohort.4 The mean FMD in their whole cohort was
4.42.8% versus 3.42.5% in incident cases, suggesting that
the improvement seen in our study is likely to have a clinical
impact on cardiovascular risk reduction in patients with RA.
Previous studies have demonstrated that intra-arterial
administration of BH4 improves endothelium-dependent
dilatation in patients with hypercholesterolemia,27 coronary
artery disease,28 and type II diabetes.29 Oral BH4 supplemen-
tation also improves endothelial function in elderly patients,30
in long-term smokers,31 and in patients with hypercholes-
terolemia32 and hypertension.33 Conversely, Cunnington et al
showed that although oral BH4 led to an 2.5-fold increase of
Table 1. Baseline Characteristics and Demographics
Acute Short Term Controls P Value*
n 18 15 33
Sex, female/male, n/n 14/4 13/2 26/7 0.5
Age, y 5513 5911 5611 0.3
RA years 1210 149 — 0.7
Weight, kg 71.414.3 70.910.1 71.816.2 0.9
BH4 dose, mg/kg 5.81.1 5.80.8 — 0.9
BMI, kg/m2 25.84.5 26.74.0 26.25.2 0.6
Systolic BP, mm Hg 12617 12513 1219 0.7
Diastolic BP, mm Hg 739 779 777 0.3
MAP, mm Hg 9212 9411 917 0.5
Heart rate, bpm 7412 6812 669† 0.1
aPWV, m/s 7.872.24 7.791.15 6.81.03† 0.9
Augmentation index, % 2612 3112 2312 0.2
Brachial diameter, mm 3.980.72 3.910.51 3.620.61† 0.8
FMD, % 3.172.68 3.671.92 6.163.63† 0.6
GTN, % 9.394.38 7.643..04 9.425.41 0.4
DAS28 4.340.92 4.051.22 — 0.5
CRP, mg/L 6.505.90 4.804.07 — 0.3
ESR, mm/h 2525 1614 — 0.2
TC, mmol/L 4.40.9 5.41.1 5.21.0 0.01
Statin, n 5 5 0 0.7
Anti–TNF-a, n 5 6 0 0.5
Methotrexate, n 8 9 0 0.4
Other DMARDs, n 9 6 0 0.6
NSAIDs, n 9 8 0 0.6
Prednisolone, n (mg/day) 7 (4.71.5) 2 (7.503.5) 0 0.1 (0.1)
Values represent meanSD. Signiﬁcance was determined using an unpaired Student t test. BMI indicates body mass index; BP, blood pressure; bpm, beats per minute; CRP, C-reactive
protein; DAS28, disease activity score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NSAIDs, nonsteroidal anti-inﬂammatory drugs; TC, total
cholesterol; TNF-a, tumor necrosis factor a.
*P value for the comparison between acute and short-term study participants.
†P<0.05 between RA patients and control participants.
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plasma BH4 levels in patients with established coronary artery
disease, it had no effect on vascular function or superoxide
production because of systemic oxidation of BH4 to BH2.
19
The impact of BH4 on endothelial function has not been
assessed previously in RA; however, other interventions (eg,
individually designed exercise program) have been shown to
improve endothelial function in RA patients.39 Because
intracellular BH4 levels are regulated by de novo synthesis
of BH4 from guanosine triphosphate and through recycling of
BH2 to BH4 via dyhydrofolate reductase,
40 use of dyhydrofo-
late reductase inhibitors (eg, disease-modifying antirheumatic
drugs, MTX) may inhibit the bioavailability of BH4 in the
endothelium. Nevertheless, we found no difference in the
effect of BH4 supplementation on endothelial function
between those RA patients on MTX and those not receiving
MTX. A trend suggested that those patients on MTX had a
greater increase in FMD following BH4 supplementation,
perhaps because of reduced levels of inﬂammation. Notably,
our study was not powered to look at this difference.
We and others have demonstrated that patients with RA
have increased aortic stiffening in comparison to healthy
participants,10,14–16 and that can be reversed with
immunomodulatory therapy.10,12,41 Our previous studies sug-
gested a link between arterial stiffness and endothelial
function,17,18 but it is unclear if this relationship is causal or
if they occur in parallel in response to common drivers such
as increased inﬂammation. Interestingly, in the present study,
neither a single dose nor short-term supplementation with
oral BH4 led to a change in aPWV, brachial pulse wave
velocity, AIx, or blood pressure in comparison to placebo. Park
et al recently demonstrated in patients with chronic kidney
disease that 6R-BH4 signiﬁcantly improved AIx
42; however,
there was also a drop in blood pressure, and it appears that
the change in AIx was not corrected for change in mean
arterial pressure, only for heart rate. Similarly, Porkert et al
showed a 15-mm Hg reduction in systolic blood pressure
following 8-week treatment with BH4 400 mg in hypertensive
patients, but this study was not placebo controlled.33 In
healthy older men, BH4 was shown to reduce carotid artery
compliance, but there was a confounding fall in systolic blood
pressure.43 In postmenopausal women, however, Moreau
et al showed an improvement in carotid artery compliance
and FMD response following a single dose of oral BH4 without
change in mean arterial pressure.44
Our study also provided evidence about causality for
endothelial function and aortic stiffness. We demonstrated
previously that under resting conditions, local NO production
modulates distensibility of muscular iliac artery in humans and
that exogenous NO increases arterial distensibility18;
however, data relating to elastic aorta are more controversial.
Table 2. Change in Disease Activity, Inﬂammation, and Hemodynamic Parameters Following BH4
Acute Short Term
BH4 Placebo
ANOVA
P Value BH4 Placebo
ANOVA
P Value
DAS28 0.020.46 0.09.43 0.4
CRP, mg/L 0.792.6 0.933.17 0.9
ESR, mm/h 07 15 0.6
SBP, mm Hg 213 610 0.1 411 48 0.9
DBP, mm Hg 37 26 0.6 05 17 0.6
MAP, mm Hg 39 58 0.2 27 37 0.8
HR, bpm 67 67 0.8 08 07 0.8
AIx, % 17 06 0.3 27 15 0.9
bPWV, m/s 0.140.74 0.090.77 0.6 0.071.14 0.250.52 0.6
aPWV, m/s 0.130.58 0.220.43 0.6 0.221.33 0.250.51 0.9
Adjusted aPWV, m/s 0.150.82 0.310.80 0.4 0.221.27 0.280.72 0.3
Brachial diameter, mm 0.140.37 0.020.40 0.2 0.170.40 0.040.39 0.3
FMD, % 3.574.14* 1.013.12 0.03 3.694.90** 0.192.51 0.02
GTN, % 2.85.1 1.82.7 0.8 0.362.02 1.332.07 0.3
Values represent mean changeSD. Signiﬁcance was determined using 2-way repeated-measures ANOVA. The effect of individual treatments was determined in post hoc tests with
Bonferroni correction for 2 comparisons when overall signiﬁcance in ANOVA was P<0.05. Results of these comparisons are indicated by asterisks. aPWV indicates aortic pulse wave
velocity; bpm, beats per minute; bPWV, brachial pulse wave velocity; CRP, C-reactive protein; DAS28, disease activity score; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation
rate; FMD, ﬂow-mediated dilatation; GTN, glyceryl trinitrate; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.
*P=0.015.
**P=0.002.
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A recent study by Butlin et al showed that exogenous NO
donor sodium nitroprusside does not alter aortic stiffness
in vivo in rats.45 Nevertheless, numerous studies,10,11,46
including ours, have demonstrated a reduction in aortic
stiffness, which mirrors the changes in endothelial function,
following anti-inﬂammatory or cholesterol-lowering therapies.
The current study clearly demonstrated that improvement of
endothelial function, without change in inﬂammation or lipids,
does not lead to reduction of aortic stiffness, strongly
suggesting that there is no direct causal link between aortic
stiffness and endothelial function. We cannot exclude the
possibility that this ﬁnding is speciﬁc to RA because previous
studies have demonstrated changes in aPWV in healthy
participants in acute models of induced inﬂammation.47,48
Limitations
We did not assess serum BH4 and BH2 levels in our study;
however, numerous studies have demonstrated that
supplementation with 6R-BH4 leads to increase in serum BH4
levels.19,32 Moreover, we chose the time points based on
published ﬁndings. Fiege et al demonstrated that the maximal
plasma biopterin levels peaked between 1 and 4 hours, with
median peak of 3 hours and maximum concentration of 258.7
to 295.0 nmol/L for 10 mg/kg; even 24 hours after adminis-
tration, 6R-BH4 levels were still 4–5 times the basal values.
35
Moreover, our treatment period of 1-week was very short, and
we can neither extrapolate these results to what may be the
chronic effects of BH4 supplementation in patients with RA nor
predict whether it may have beneﬁcial effects on future
cardiovascular events.
Conclusion
This study shows for the ﬁrst time in patients with RA that oral
BH4 improves endothelial function as measured by a response
to reactive hyperemia. These ﬁndings suggest that recoupling of
eNOS using cofactor BH4 may provide a rational therapeutic
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Figure 2. The effect of BH4 400 mg. Data represent means and SEM. Signiﬁcance was determined using 2-way repeated-measures ANOVA and
Bonferroni-corrected post hoc tests. Red represents BH4; blue represents placebo. A, Endothelial function was measured before and 3 hours after
BH4 and placebo in randomorder. ANOVA: P=0.03 between groups; post hoc BH4: P=0.015; placebo: P=0.5. B, Aortic stiffness wasmeasured before
and 3 hours after BH4 and placebo in random order. ANOVA between groups: P=0.6; post hoc BH4: P=0.5; placebo: P=0.6. C, Endothelial function
wasmeasured before and 7 days after BH4 and placebo in random order. ANOVA between groups: P=0.02; post hoc BH4: P=0.002; placebo: P=0.4.
D, Aortic stiffness was measured before and 7 days after BH4 and placebo in random order. ANOVA between groups: P=0.9; post hoc BH4: P=0.5;
placebo: P=0.5. aPWV indicates aortic pulse wave velocity; BH4, tetrahydrobiopterin; FMD, ﬂow-mediated dilatation.
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approach to prevent CVD in patients with chronic inﬂammatory
diseases. BH4 supplementation did not appear to reduce aortic
stiffness, suggesting that endothelial dysfunction is not a
pathophysiology behind aortic stiffening in RA and that these
conditionsmay just exist in parallel, both inﬂuenced by common
risk factors such as inﬂammation and increased reactive
oxygen species production.
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